· ONCOS-102 in combination with PD-1 checkpoint inhibitor (CPI) Keytruda
demonstrated strong ORR of 35% in PD-1 CPI resistant melanoma, correlating with
robust and persistent immune activation
  · A phase 2 trial is under planning, where ONCOS-102 will be tested in a
triple-combination with both PD-1 and CTLA-4 CPIs

Oslo, Norway, 20 October 2022 - Targovax ASA (OSE: TRVX), a clinical-stage
immuno-oncology company developing immune activators to target solid tumors,
today announces that the completed ONCOS-102 phase 1b study in PD-1 CPI
resistant advanced melanoma has been published in the prestigious oncology
journal Clinical Cancer Research, published by the American Association for
Cancer Research (AACR).

PD-1 CPI resistant advanced melanoma is a major unmet medical need affecting up
to 25,000 patients per year in the major markets. The diagnosis is associated
with a poor prognosis and there are currently no approved treatment options
available.

In this phase 1b trial, ONCOS-102 was given intra-tumorally to 21 PD-1 CPI
resistant melanoma patients, followed by re-treatment with the PD-1 CPI
Keytruda. It is anticipated that local injection of ONCOS-102 will induce an
inflammatory immune response in the tumor microenvironment and drive systemic T
-cell activation, which in turn can re-sensitize the patient to PD-1 CPI
therapy.

As expected, ONCOS-102 generated strong and durable immune activation in the
treated patients, which translated into a promising objective response rate
(ORR) of 35%. Importantly, the clinical efficacy was associated with continuous
replication of ONCOS-102 within the tumor, statistically significant increase in
T-cell infiltration, and broad and persistent upregulation of immunological
pathways in responding patients.

Dr. Alexander Shoushtari, Memorial Sloan Kettering Cancer Center, New York said:
"Checkpoint inhibitors have had a significant impact on the way we treat
melanoma